ArticleFuture oncology (London, England)2025

Prevalence of medical conditions or comorbidities influencing first-line therapy in unresectable hepatocellular carcinoma in the United States.

Tammy A Schuler et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.